Phase II trial of carboplatin and pemetrexed as first-line chemotherapy for non-squamous non-small cell lung cancer, and correlation between the efficacy/toxicity and genetic polymorphisms associated with pemetrexed metabolism: Hokkaido Lung Cancer Clinical Study Group Trial (HOT) 0902.
作者： Kenya Kanazawa , , Hiroshi Yokouchi , Xintao Wang , Takashi Ishida
DOI: 10.1007/S00280-014-2589-3
关键词:
摘要: Purpose This phase II study evaluated the response rate (RR) and safety of combination therapy with carboplatin (CBDCA) pemetrexed (PEM) in Japanese patients non-squamous non-small cell lung cancer (non-sq NSCLC). Further, relationship between efficacy/toxicity genetic polymorphisms associated PEM metabolism was analyzed.
springer.com
sci-hub.se 参考文章(45)
Damali N Martin, Brenda J Boersma, Tiffany M Howe, Julie E Goodman, Leah E Mechanic, Stephen J Chanock, Stefan Ambs, Association of MTHFR gene polymorphisms with breast cancer survival BMC Cancer. ,vol. 6, pp. 257- 257 ,(2006) , 10.1186/1471-2407-6-257
Go Watanabe, Kazuyuki Kawakami, Identification and functional analysis of single nucleotide polymorphism in the tandem repeat sequence of thymidylate synthase gene. Cancer Research. ,vol. 63, pp. 6004- 6007 ,(2003)
Ronald S. Go, Alex A. Adjei, Review of the Comparative Pharmacology and Clinical Activity of Cisplatin and Carboplatin Journal of Clinical Oncology. ,vol. 17, pp. 409- 409 ,(1999) , 10.1200/JCO.1999.17.1.409
C. Manegold, U. Gatzemeier, J. von Pawel, R. Pirker, R. Malayeri, J. Blatter, K. Krejcy, Front-line treatment of advanced non-small-cell lung cancer with MTA (LY231514, Pemetrexed disodium, ALIMTA™ and cisplatin: A multicenter phase II trial Annals of Oncology. ,vol. 11, pp. 435- 440 ,(2000) , 10.1023/A:1008336931378
Hiroshi Hashimoto, Yuichi Ozeki, Mitsuharu Sato, Kiyohaya Obara, Noriyuki Matsutani, Yoshinori Nakagishi, Toshiro Ogata, Tadaaki Maehara, Significance of thymidylate synthase gene expression level in patients with adenocarcinoma of the lung. Cancer. ,vol. 106, pp. 1595- 1601 ,(2006) , 10.1002/CNCR.21777
Radj Gervais, Gilles Robinet, Christelle Clément-Duchêne, Fabrice Denis, Claude El Kouri, Philippe Martin, Nadia Chouaki, Nawel Bourayou, Jean-François Morère, Pemetrexed and carboplatin, an active option in first-line treatment of elderly patients with advanced non-small cell lung cancer (NSCLC): A phase II trial Lung Cancer. ,vol. 80, pp. 185- 190 ,(2013) , 10.1016/J.LUNGCAN.2013.01.008
Masayuki Takeda, Isamu Okamoto, Naoko Hirabayashi, Mami Kitano, Kazuhiko Nakagawa, Thymidylate synthase and dihydropyrimidine dehydrogenase expression levels are associated with response to S-1 plus carboplatin in advanced non-small cell lung cancer Lung Cancer. ,vol. 73, pp. 103- 109 ,(2011) , 10.1016/J.LUNGCAN.2010.10.022
Ralph G. Zinner, Frank V. Fossella, Gregory W. Gladish, Bonnie S. Glisson, George R. Blumenschein, Vassiliki A. Papadimitrakopoulou, Katherine M.W. Pisters, Edward S. Kim, Yun W. Oh, Beverly O. Peeples, Zhishen Ye, Rafael E. Curiel, Coleman K. Obasaju, Waun K. Hong, Roy S. Herbst, Phase II study of pemetrexed in combination with carboplatin in the first-line treatment of advanced nonsmall cell lung cancer. Cancer. ,vol. 104, pp. 2449- 2456 ,(2005) , 10.1002/CNCR.21480
Alessandra Bearz, Diego Serraino, Lucia Fratino, Massimiliano Berretta, Umberto Tirelli, Recent improvement in the survival of patients with advanced nonsmall cell lung cancer enrolled in phase III trials of first‐line, systemic chemotherapy Cancer. ,vol. 110, pp. 2593- 2593 ,(2007) , 10.1002/CNCR.23063
Frances A. Shepherd, Janet Dancey, Andrew Arnold, Alan Neville, James Rusthoven, Robert D. Johnson, Bryn Fisher, Elizabeth Eisenhauer, Phase II study of pemetrexed disodium, a multitargeted antifolate, and cisplatin as first-line therapy in patients with advanced nonsmall cell lung carcinoma: a study of the National Cancer Institute of Canada Clinical Trials Group. Cancer. ,vol. 92, pp. 595- 600 ,(2001) , 10.1002/1097-0142(20010801)92:3<595::AID-CNCR1359>3.0.CO;2-D